Amarin Corporation Plc (DE:EH3)
NASDAQ:EH3
EH3 Stock Chart & Stats
€12.30
--
Market closed
€12.30
--
Day’s Range― - ―
52-Week Range€10.30 - €17.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.00
Market Cap
€261.50M
Enterprise Value€174.22M
Total Cash (Recent Filing)€307.82M
Total Debt (Recent Filing)€5.58M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 05, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.54
Shares Outstanding20,969,109
10 Day Avg. Volume5
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.63
Price to Sales (P/S)1.36
P/FCF Ratio42.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€149.41M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe total revenues included a $25M upfront payment from the Recordati deal, contributing to the overall revenue growth.
Strategic PartnershipsThe Recordati partnership in Europe helps reshape Amarin's business model by transferring commercialization to a seasoned local partner with established cardiovascular infrastructure and expertise.
Bears Say
Competition ChallengesThe longer-term outlook for the US Vascepa business remains conservative given growing pressure from generic competitors.
Market CompetitionInvestors may remain cautious about the commercial business as the US VASCEPA franchise continues to face significant pressure from at least eight generic competitors.
Amarin News
EH3 FAQ
What was Amarin Corporation Plc’s price range in the past 12 months?
Amarin Corporation Plc lowest stock price was €10.30 and its highest was €17.20 in the past 12 months.
What is Amarin Corporation Plc’s market cap?
Amarin Corporation Plc’s market cap is €261.50M.
When is Amarin Corporation Plc’s upcoming earnings report date?
Amarin Corporation Plc’s upcoming earnings report date is Aug 05, 2026 which is in 61 days.
How were Amarin Corporation Plc’s earnings last quarter?
Amarin Corporation Plc released its earnings results on Apr 29, 2026. The company reported -€0.026 earnings per share for the quarter, missing the consensus estimate of €0.009 by -€0.034.
Is Amarin Corporation Plc overvalued?
According to Wall Street analysts Amarin Corporation Plc’s price is currently Overvalued.
Does Amarin Corporation Plc pay dividends?
Amarin Corporation Plc does not currently pay dividends.
What is Amarin Corporation Plc’s EPS estimate?
Amarin Corporation Plc’s EPS estimate is -0.01.
How many shares outstanding does Amarin Corporation Plc have?
Amarin Corporation Plc has 20,969,109 shares outstanding.
What happened to Amarin Corporation Plc’s price movement after its last earnings report?
Amarin Corporation Plc reported an EPS of -€0.026 in its last earnings report, missing expectations of €0.009. Following the earnings report the stock price went down -0.847%.
Which hedge fund is a major shareholder of Amarin Corporation Plc?
Currently, no hedge funds are holding shares in DE:EH3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amarin Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.58%
12-Months-Change
Fundamentals
Return on Equity
-7.34%
Trailing 12-Months
Asset Growth
-1.51%
Trailing 12-Months
Company Description
Amarin Corporation Plc
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
EH3 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear operational progress: revenue growth, meaningful expense reductions, improved operating losses, second consecutive quarter of positive operating cash flow, a strong cash position with no debt, and accelerating international traction via the Recordati partnership. Offsetting risks include materially higher COGS in the near term (62% YoY increase), quarter-to-quarter revenue variability from the partnered model, ongoing U.S. generic competition risk, and remaining restructuring charges. On balance, the positive developments (cash generation, cost savings, market-share gains, favorable guideline positioning, and international rollout momentum) outweigh the near-term headwinds.View all DE:EH3 earnings summariesTechnical Analysis
Altimmune
―
Rigel
―
Aldeyra Therapeutics
―
Rocket Pharmaceuticals
―
Corvus Pharmaceuticals
―
Options Prices
Currently, No data available
---